TY - JOUR T1 - Six of 12 Relapsed or Refractory Indolent Lymphoma Patients Treated 10 Years Ago with <sup>131</sup>I-Tositumomab Remain in Complete Remission JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 896 LP - 900 DO - 10.2967/jnumed.111.087460 VL - 52 IS - 6 AU - Franz Buchegger AU - Cristian Antonescu AU - Claudine Helg AU - Marek Kosinski AU - John O. Prior AU - Angelika Bischof Delaloye AU - Oliver W. Press AU - Nicolas Ketterer Y1 - 2011/06/01 UR - http://jnm.snmjournals.org/content/52/6/896.abstract N2 - The purpose of our study was to update the safety and efficacy results of radioimmunotherapy in relapsed or resistant indolent or transformed non-Hodgkin lymphoma. Methods: More than 9 y ago, we treated 12 indolent and 4 transformed, relapsed or refractory lymphoma patients with a single administration of nonmyeloablative therapy with tositumomab and 131I-tositumomab. The 16 patients had a mean of 3.1 (range, 1–6) previous chemotherapy and antibody treatments. Results: Six of 12 relapsed indolent lymphoma patients remain disease-free a mean of 9.8 y (range, 8.6–10.7 y) after radioimmunotherapy. Three of 4 transformed lymphoma patients progressed after radioimmunotherapy, and 1 patient had a partial response of 10 mo. Conclusion: Optimal patient benefit might be obtained in indolent lymphoma when administering radioimmunotherapy up-front in combination with chemotherapy and rituximab treatment. However, these results show that radioimmunotherapy alone achieved long-lasting remissions in 6 of 12 (50%) indolent lymphoma patients in relapse after 1 or multiple chemotherapies. ER -